RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.
Read original at benzingaStocks · News reference
Guggenheim Maintains Buy on Biogen, Raises Price Target to $280
Guggenheim analyst Brad Canino maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $260 to $280.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 1:48 PM
- Checked
- Jul 21, 2026, 1:48 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Eisai And Biogen Announce Once Weekly Lecanemab-Irmb Subcutaneous Injection Is Now Available In U.S. For Initiation Therapy For Early Alzheimer’s Disease
Read original at benzingaWolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target
Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.
Read original at benzingaBiogen Completes Acquisition of RayThera Inc.
Biogen Inc. announced the completion of its acquisition of RayThera Inc., a privately held biotechnology company specializing in small-molecule immunology therapies. The acquisition adds multiple assets to Biogen's immunology portfolio, with the lead program entering Phase 1 development in July 2026. The company views this as part of its strategic growth in immunology and its open innovation model.
Read original at globenewswire-inc